Publicacions (82) Publicacions de EVA RAMOS ALONSO

2023

  1. C-glycosides analogues of the okadaic acid central fragment exert neuroprotection via restoration of PP2A-phosphatase activity: A rational design of potential drugs for Alzheimer's disease targeting tauopathies

    European Journal of Medicinal Chemistry, Vol. 251

  2. Melatonin as Modulator for Sulfur and Nitrogen Mustard-Induced Inflammation, Oxidative Stress and DNA Damage: Molecular Therapeutics

    Antioxidants, Vol. 12, Núm. 2

  3. Melatonin: A multitasking indoleamine to modulate hippocampal neurogenesis

    Neural Regeneration Research, Vol. 18, Núm. 3, pp. 503-505

  4. Non-Excitatory Amino Acids, Melatonin, and Free Radicals: Examining the Role in Stroke and Aging

    Antioxidants, Vol. 12, Núm. 10

  5. POTENTIAL OF MELATONIN TO REVERSE EPIGENETIC ABERRATIONS IN ORAL CANCER: NEW FINDINGS

    EXCLI Journal, Vol. 22, pp. 1280-1310

  6. Redox Regulation of Microglial Inflammatory Response: Fine Control of NLRP3 Inflammasome through Nrf2 and NOX4

    Antioxidants, Vol. 12, Núm. 9

  7. Therapeutic Potential of Melatonin Counteracting Chemotherapy-Induced Toxicity in Breast Cancer Patients: A Systematic Review

    Pharmaceutics, Vol. 15, Núm. 6

2022

  1. Coronavirus Disease 2019 (COVID-19) and Its Neuroinvasive Capacity: Is It Time for Melatonin?

    Cellular and Molecular Neurobiology, Vol. 42, Núm. 3, pp. 489-500

  2. Synthesis and Pharmacological Evaluation of New N-Sulfonylureas as NLRP3 Inflammasome Inhibitors: Identification of a Hit Compound to Treat Gout

    Journal of Medicinal Chemistry, Vol. 65, Núm. 8, pp. 6250-6260

2021

  1. In Silico Prediction of the Toxic Potential of Neuroprotective Bifunctional Molecules Based on Chiral N-Propargyl-1,2-amino Alcohol Derivatives

    Chemical Research in Toxicology, Vol. 34, Núm. 5, pp. 1245-1249

  2. The coronavirus disease 2019 (Covid-19): Key emphasis on melatonin safety and therapeutic efficacy

    Antioxidants, Vol. 10, Núm. 7

  3. Toxicology of Blister Agents: Is Melatonin a Potential Therapeutic Option?

    DISEASES, Vol. 9, Núm. 2

2020

  1. Cerebral ischemia and traumatic brain injury: Protection by melatonin

    Melatonin: Production, Functions and Benefits (Nova Science Publishers, Inc.), pp. 231-255

  2. Highlights of ASS234: A novel and promising therapeutic agent for Alzheimer's disease therapy

    Neural Regeneration Research, Vol. 15, Núm. 1, pp. 30-35

  3. In Vitro and in Silico ADME-Tox Profiling and Safety Significance of Multifunctional Monoamine Oxidase Inhibitors Targeting Neurodegenerative Diseases

    ACS Chemical Neuroscience, Vol. 11, Núm. 22, pp. 3793-3801

  4. Melatonin and neurodegeneration: From neurotoxic environment to cell resilience

    Advances in Molecular Toxicology (Elsevier B.V.), pp. 69-108

  5. Melatonin reduces NLRP3 inflammasome activation by increasing α7 nAChR-mediated autophagic flux

    Antioxidants, Vol. 9, Núm. 12, pp. 1-18

  6. Melatonin's efficacy in stroke patients; a matter of dose? A systematic review

    Toxicology and Applied Pharmacology, Vol. 392

2019

  1. New flavonoid–N,N-dibenzyl(N-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties

    Journal of Enzyme Inhibition and Medicinal Chemistry, Vol. 34, Núm. 1, pp. 712-727

  2. Potential of melatonin as adjuvant therapy of oral cancer in the era of epigenomics

    Cancers, Vol. 11, Núm. 11